Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash from Operations (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Cash from Operations for 6 consecutive years, with 67899000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations rose 11.52% year-over-year to 67899000.0, compared with a TTM value of 254179000.0 through Sep 2025, down 31.58%, and an annual FY2024 reading of 206271000.0, down 41.68% over the prior year.
  • Cash from Operations was 67899000.0 for Q3 2025 at Autolus Therapeutics, up from 72781000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 14566000.0 in Q4 2022 and bottomed at 76740000.0 in Q3 2024.
  • Average Cash from Operations over 4 years is 48555750.0, with a median of 41466500.0 recorded in 2023.
  • The sharpest move saw Cash from Operations tumbled 90.95% in 2024, then rose 11.52% in 2025.
  • Year by year, Cash from Operations stood at 14566000.0 in 2022, then plummeted by 70.49% to 24833000.0 in 2023, then tumbled by 52.76% to 37934000.0 in 2024, then tumbled by 78.99% to 67899000.0 in 2025.
  • Business Quant data shows Cash from Operations for AUTL at 67899000.0 in Q3 2025, 72781000.0 in Q2 2025, and 75565000.0 in Q1 2025.